CN114470235B - Application of bismuth-based metal organic framework material as light-operated drug carrier - Google Patents
Application of bismuth-based metal organic framework material as light-operated drug carrier Download PDFInfo
- Publication number
- CN114470235B CN114470235B CN202210056615.0A CN202210056615A CN114470235B CN 114470235 B CN114470235 B CN 114470235B CN 202210056615 A CN202210056615 A CN 202210056615A CN 114470235 B CN114470235 B CN 114470235B
- Authority
- CN
- China
- Prior art keywords
- bismuth
- light
- drug
- based metal
- metal organic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention discloses an application of bismuth-based metal organic framework material in light-controlled drug carrier, and the application of SU-101 in light-controlled drug carrier, because drug molecules and carbonyl oxygen in SU-101 form hydrogen bond, the light has higher drug loading capacity, in addition, the electron structure can be changed by illumination, the electron cloud density of the carbonyl oxygen in SU-101 is reduced, and the hydrogen bond between the drug molecules and the SU-101 carbonyl is broken, thereby realizing light-controlled drug release, and controlling the drug release amount by adjusting illumination time and light wavelength.
Description
Technical Field
The invention belongs to the technical field of drug carriers, and particularly relates to application of bismuth-based metal organic framework materials as light-controlled drug carriers.
Background
The statements herein merely provide background information related to the present disclosure and may not necessarily constitute prior art.
Drug therapy is still the main method of clinical treatment at present, generally, the traditional administration method needs to be periodically administered, and the nonspecific distribution of drugs in the body can lead to the problems of high dosage, high clearance rate, large side effect and the like.
The existing drug carrier materials are mainly divided into inorganic materials (zeolite, fe 3 O 4 Mesoporous silica and gold nanomaterials) and organic materials (liposomes, micelles, gels and vesicles), however, these materials have problems of poor stability, uncontrolled release, poor biocompatibility, etc., which limit their wide application. In recent years scientists have proposed the idea of porous metal-organic frameworks (MOFs) as ideal controlled drug carriers. The stimuli currently available for controlled release of drugs mainly include chemicals (pH, glucose or the presence of specific enzymes), light, heat, magnetism, ultrasound and mechanical forces, which can be used to control the drug delivery rate of biological materials. Each stimulus can be simply and accurately controlled externally or internally as a stimulus for drug release. There is currently no viable solution for a controlled drug carrier using light as stimulus.
Disclosure of Invention
Aiming at the defects existing in the prior art, the invention aims to provide the application of the bismuth-based metal organic framework material as a light-controlled drug carrier.
In order to achieve the above object, the present invention is realized by the following technical scheme:
in a first aspect, the present invention provides the use of a bismuth-based metal organic framework material as a photo-controlled drug carrier.
In a second aspect, the present invention provides a pharmaceutical carrier comprising the bismuth-based metal-organic framework material.
In a third aspect, the present invention provides a light-controlled release drug comprising a bismuth-based metal-organic framework material and a drug supported on the bismuth-based metal-organic framework material.
In a fourth aspect, the present invention provides a method of drug adsorption comprising the steps of: adding the bismuth-based metal organic framework material and/or the drug carrier into the drug solution for adsorption, and performing solid-liquid separation after the adsorption is finished.
In a fifth aspect, the present invention provides a light-operated drug delivery device comprising: a bismuth-based metal organic framework loaded with a drug and an illumination device.
The beneficial effects achieved by the above one or more embodiments of the present invention are as follows:
the application of the bismuth-based metal organic frame material as the light-controlled drug carrier is disclosed for the first time, as the drug molecules and the carbonyl oxygen in the bismuth-based metal organic frame material form hydrogen bonds, the bismuth-based metal organic frame material has higher drug loading capacity, in addition, the electronic structure of the bismuth-based metal organic frame material can be changed by illumination, the electron cloud density of the carbonyl oxygen in the bismuth-based metal organic frame material is reduced, and the hydrogen bonds between the drug molecules and the carbonyl of the bismuth-based metal organic frame material are broken, so that the light-controlled drug release is realized, and the control of the drug release amount can be realized by adjusting the illumination time and the light wavelength.
Light can be applied remotely with extremely high spatial and temporal precision, and furthermore, a wide range of parameters (wavelength, light intensity, exposure time and beam diameter) can be adjusted to modulate the drug release.
Drawings
The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the description serve to explain the invention.
FIG. 1 is a graph showing the density-functional theory of bismuth-based metal organic framework material according to example 1, wherein a is TDOS and PDOS with different atoms, and b is TDOS and PDOS with different oxygen atoms;
FIG. 2 is a graph showing the result of the adsorption effect verification of ciprofloxacin in example 2 of the present invention;
FIG. 3 is a graph showing the result of verifying the effect of light control release of ciprofloxacin in example 3 of the present invention, wherein a is the dynamic process of ciprofloxacin release under full-light (full), visible light (vis) and near-infrared light (NIR) irradiation, b is the comparative graph of the total ciprofloxacin release under full-light (full), visible light (vis) and near-infrared light (NIR) irradiation, and c is the comparative graph of ciprofloxacin release under monochromatic light of different wavelengths;
FIG. 4 is a schematic diagram of the bismuth-based metal organic framework of the present invention for drug loading and optically controlled release;
FIG. 5 is a graph (b) showing the adsorption capacity (a) of the bismuth-based metal organic framework material of example 4 for different drugs (CIP: ciprofloxacin, NOR: norfloxacin, TET: tetracycline, DOX: doxorubicin hydrochloride, AMO: amoxicillin) and the release amounts of the different drugs under total light.
Detailed Description
It should be noted that the following detailed description is illustrative and is intended to provide further explanation of the invention. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
In a first aspect, the present invention provides the use of a bismuth-based metal organic framework material as a photo-controlled drug carrier.
The bismuth-based metal organic framework material is bismuth-based MOFs synthesized by taking ellagic acid as an organic ligand and bismuth acetate as a bismuth source. The preparation method comprises the following steps: the specific preparation method is as follows: ellagic acid, bismuth acetate and acetic acid aqueous solution with volume fraction of 6% are stirred at room temperature for 48 hours to obtain the final product.
The bismuth-based metal organic frame material has the advantages of good chemical stability, no toxicity, biocompatibility, particle size suitable for intravenous administration and photosensitivity, and the medicine molecules can form hydrogen bonds with carbonyl oxygen in the bismuth-based metal organic frame material to improve medicine adsorption capacity.
The bismuth-based metal organic framework material has higher drug loading and light irradiation can control drug release, and can adjust the drug release amount by changing the light irradiation time and wavelength, and the schematic diagram of the bismuth-based metal organic framework material on drug loading and light-controlled drug release is shown in figure 4.
In some embodiments, the drug includes, but is not limited to, ciprofloxacin, norfloxacin, tetracycline, doxorubicin hydrochloride, and amoxicillin.
In a second aspect, the present invention provides a pharmaceutical carrier comprising the bismuth-based metal-organic framework material.
In a third aspect, the present invention provides a light-operated drug delivery device, characterized in that: comprises bismuth-based metal-organic frame material and medicine loaded on the bismuth-based metal-organic frame material;
preferably, the drugs include, but are not limited to, ciprofloxacin, norfloxacin, tetracycline, doxorubicin hydrochloride, and amoxicillin;
preferably, the drug is ciprofloxacin, norfloxacin or doxorubicin hydrochloride;
further preferably, the drug is ciprofloxacin or norfloxacin.
In a fourth aspect, the present invention provides a method of drug adsorption comprising the steps of: adding the bismuth-based metal organic framework material and/or the drug carrier into the drug solution for adsorption, and performing solid-liquid separation after the adsorption is finished.
In some embodiments, the drug includes, but is not limited to, ciprofloxacin, norfloxacin, tetracycline, doxorubicin hydrochloride, and amoxicillin;
preferably, the drug is ciprofloxacin, norfloxacin or doxorubicin hydrochloride;
further preferably, the drug is ciprofloxacin or norfloxacin.
In some embodiments, the drug adsorption process is stirring adsorption in the dark.
Further, the concentration of the drug solution is 2.5-20mg/L.
Further, the mass percentage of the bismuth-based metal organic framework material and/or the drug carrier added into the drug solution is 0.02% -0.07%.
In some embodiments, the temperature of the drug solution is 15-25 ℃.
In a fifth aspect, the present invention provides a light-operated drug delivery device comprising: a bismuth-based metal organic framework loaded with a drug and an illumination device.
In some embodiments, the illumination device is a plenoptic light source or a monochromatic light source.
The technical scheme of the invention is described below through specific examples. The starting materials used in the examples below are all commercially available.
Example 1
Theoretical calculation:
DFT calculations were performed using the Vienna from scratch simulation software package (VASP) and the frozen-tuberculosis full-electronic projection enhanced wave (PAW) method. The exchange and correlation potentials are described using a Generalized Gradient Approximation (GGA) Perdew-Burke-Ernzerhof (PBE). The cut-off energy of the plane wave basis set was set to 450eV. The C28Bi4O26, monkhorst-Pack k-point samples were set to 1X 3 using the primordial cells. Geometric optimization is performed until the force on each ion is reduced to
The following is given. The resulting structure is used to calculate an electronic structure.
The electronic structure of SU-101 (as shown in fig. 1) is revealed by calculating the total state density (TDOS) and the local state density (PDOS). As can be seen from the TDOS diagram, the band gap of Bi-MBA is calculated to be 1.6eV, which is slightly smaller than the test result of ultraviolet-visible diffuse reflection analysis. It can be seen from the PDOS diagram that Bi atoms contribute little to the boundary orbitals, whereas the broad valence and conduction bands in organic ligands consist mainly of O and C atoms. Furthermore, it was found through research on PDOS of different oxygen atoms that O3 (oxygen atom in carbonyl group) contributed only to the valence band, whereas other oxygen atoms O2 and O4 contributed not only to the valence band but also to the conduction band. While O1 and O5 contribute less to the conduction and valence bands. This means that the electron cloud density of O3 under light will decrease, which is the cause of hydrogen bond breakage.
Example 2
Ciprofloxacin drug adsorption:
bismuth-based metal organic framework material (SU-101) (25 mg) powder was added to ciprofloxacin aqueous solution (50 mL,10 mg/L), stirred in the dark, and the adsorption process was performed at room temperature (25 ℃). During the adsorption, 1.5mL of the suspension was withdrawn every 30 min. After centrifugation, the absorbance change of the solution at 270nm was measured with an ultraviolet-visible spectrophotometer (UV-2550, shimadzu).
In this example, SU-101 was used as a drug carrier for ciprofloxacin, and had the highest adsorption capacity for 10mg/L ciprofloxacin solution, and reached adsorption-desorption equilibrium for 3 hours, with an adsorption capacity of 71%, as shown in FIG. 2.
Example 3
Light-controlled ciprofloxacin drug release
1. Full light drug release experiments
SU-101 (25 mg) powder was added to ciprofloxacin aqueous solution (50 mL,10 mg/L) and stirred in the dark for 3h to establish adsorption-desorption equilibrium, and the adsorption process was performed at room temperature (25 ℃). A300W xenon arc lamp was used as the light source, and 1.5mL of the suspension was withdrawn every 30 min. After centrifugation, the absorbance change of the solution at 270nm was measured with an ultraviolet-visible spectrophotometer (UV-2550, shimadzu).
2. Drug release assay under visible light
SU-101 (25 mg) powder was added to ciprofloxacin aqueous solution (50 mL,10 mg/L) and stirred in the dark for 3h to establish adsorption-desorption equilibrium, and the adsorption process was performed at room temperature (25 ℃). A300W xenon arc lamp equipped with a 420nm cutoff filter was used as a light source, and 1.5mL of the suspension was taken out every 30 minutes. After centrifugation, the absorbance change of the solution at 270nm was measured with an ultraviolet-visible spectrophotometer (UV-2550, shimadzu).
3. Drug release assay in near infrared light
SU-101 (25 mg) powder was added to ciprofloxacin aqueous solution (50 mL,10 mg/L) and stirred in the dark for 3h to establish adsorption-desorption equilibrium, and the adsorption process was performed at room temperature (25 ℃). A300W xenon arc lamp equipped with an 800nm cut filter was used as a light source, and 1.5mL of the suspension was taken out every 30 minutes. After centrifugation, the absorbance change of the solution at 270nm was measured with an ultraviolet-visible spectrophotometer (UV-2550, shimadzu).
4. Medicine release experiment under monochromatic light
SU-101 (25 mg) powder was added to ciprofloxacin aqueous solution (50 mL,10 mg/L) and stirred in the dark for 3h to establish adsorption-desorption equilibrium, and the adsorption process was performed at room temperature (25 ℃). As light source, a 5w monochromator (which can produce monochromatic light at 365nm, 385nm, 420nm, 450nm, 485nm, 520nm, 595nm and 630 nm) was used, and 1.5mL of the suspension was withdrawn every 30 min. After centrifugation, the absorbance change of the solution at 270nm was measured with an ultraviolet-visible spectrophotometer (UV-2550, shimadzu).
In this example, the experiment shows that the release amount of ciprofloxacin under the condition of full light is the highest and reaches 95.56%, the release amount of ciprofloxacin is 36.36% in visible light, almost no ciprofloxacin is released under near infrared light, and further the experiment of drug release by monochromatic light with different wavelengths is performed, so that the influence of light with different wavelengths on the release amount of the drug is found to be consistent with the light absorption capacity of SU-101 (as shown in fig. 3 c).
Example 4
Adsorption experiments of five drugs:
five parts of bismuth-based metal organic framework material (SU-101) (25 mg) powder were added to aqueous solutions (50 mL,15 mg/L) of ciprofloxacin, norfloxacin, tetracycline, doxorubicin hydrochloride and amoxicillin, respectively, stirred in the dark, the adsorption process was carried out at room temperature (28 ℃) and after 3 hours of stirring adsorption, 1.5mL of suspension was taken out of each aqueous solution of the drug. After centrifugation, the absorbance change of the solution at 270nm was measured with an ultraviolet-visible spectrophotometer (UV-2550, shimadzu).
Full light drug release experiments for five drugs:
five parts of bismuth-based metal organic framework material (SU-101) (25 mg) powder are added to aqueous solutions (50 mL,9 mg/L) of ciprofloxacin, norfloxacin, tetracycline, doxorubicin hydrochloride and amoxicillin respectively, and stirred in the dark for 3 hours to establish adsorption-desorption equilibrium, and the adsorption process is carried out at room temperature (22 ℃).
After the adsorption was completed, 1.5mL of each drug solution was withdrawn every 30min using a 300W xenon arc lamp as a light source. After centrifugation, the absorbance change of the solution at 270nm was measured with an ultraviolet-visible spectrophotometer (UV-2550, shimadzu).
FIG. 5 is a graph (b) showing the adsorption capacity (a) of bismuth-based metal organic framework materials for different drugs (CIP: ciprofloxacin, NOR: norfloxacin, TET: tetracycline, DOX: doxorubicin hydrochloride, AMO: amoxicillin) and the release amounts of the different drugs under total light. As shown in fig. 5, the adsorption rate of the bismuth-based metal organic framework material to ciprofloxacin can reach 85.8%, and the full-light drug release rate can reach 95.56%; the absorption rate of the norfloxacin can reach 91 percent, and the full-light drug release rate can reach 95.45 percent; the highest adsorption rate of amoxicillin is 27.9%, and the full-light drug release rate reaches 100%; the highest adsorption rate to the tetracycline is 23.2%, and the full-light drug release rate reaches 100%; the absorption rate of the doxorubicin hydrochloride is 91% at the maximum, and the full-light drug release rate is 78% at the maximum.
Therefore, the bismuth-based metal organic framework material has better adsorption and light-control release rates of ciprofloxacin and norfloxacin and slightly worse light-control release rate of doxorubicin hydrochloride.
The above description is only of the preferred embodiments of the present invention and is not intended to limit the present invention, but various modifications and variations can be made to the present invention by those skilled in the art. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (3)
1. Use of a composition comprising a bismuth-based metal organic framework material and a drug loaded onto the bismuth-based metal organic framework material for the preparation of a light-controlled release drug, characterized in that:
the bismuth-based metal organic framework material is bismuth-based MOFs synthesized by taking ellagic acid as an organic ligand and bismuth acetate as a bismuth source;
the bismuth-based metal organic framework material has photosensitivity, light control drug release is realized through illumination, and the drug release amount is controlled through adjusting illumination time and light wavelength;
the medicine is ciprofloxacin, norfloxacin, tetracycline, doxorubicin hydrochloride or amoxicillin.
2. The use according to claim 1, wherein: the medicine is ciprofloxacin, norfloxacin or doxorubicin hydrochloride.
3. The use according to claim 2, wherein: the medicine is ciprofloxacin or norfloxacin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210056615.0A CN114470235B (en) | 2022-01-18 | 2022-01-18 | Application of bismuth-based metal organic framework material as light-operated drug carrier |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210056615.0A CN114470235B (en) | 2022-01-18 | 2022-01-18 | Application of bismuth-based metal organic framework material as light-operated drug carrier |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114470235A CN114470235A (en) | 2022-05-13 |
| CN114470235B true CN114470235B (en) | 2023-05-30 |
Family
ID=81472097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210056615.0A Active CN114470235B (en) | 2022-01-18 | 2022-01-18 | Application of bismuth-based metal organic framework material as light-operated drug carrier |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114470235B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114984254B (en) * | 2022-06-08 | 2023-06-27 | 上海交通大学医学院附属第九人民医院 | Photoacoustic imaging contrast agent and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106540750A (en) * | 2016-10-21 | 2017-03-29 | 山东大学 | With visible light-responded small numerator modified catalysis material and preparation method |
| CN108619081A (en) * | 2018-05-22 | 2018-10-09 | 浙江理工大学 | A kind of photosensitive micropin and preparation method thereof, controlled release method |
| CN110787792A (en) * | 2019-11-19 | 2020-02-14 | 常州大学 | Bi with visible light response2Ti2O7-TiO2Preparation method of/RGO nano composite material |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6731404B2 (en) * | 2014-10-14 | 2020-07-29 | ザ ユニバーシティ オブ シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiation therapy, chemotherapy, immunotherapy, and any combination thereof |
| CN105770893B (en) * | 2014-12-17 | 2019-04-05 | 中国科学院宁波材料技术与工程研究所 | A kind of bismuthino composite nano materials and its diagnosing tumor and treatment use |
| KR102561737B1 (en) * | 2015-02-03 | 2023-07-31 | 유니버시티 코트 오브 더 유니버시티 오브 세인트 앤드류스 | Compositions containing NO |
| CN112521618B (en) * | 2020-10-30 | 2021-10-12 | 山东大学 | Bismuth-based metal organic framework material and preparation method and application thereof |
| CN112315975A (en) * | 2020-10-30 | 2021-02-05 | 国家纳米科学中心 | Acid-responsive polymer modified bismuth elementary nanosheet carrying nucleic acid molecules and preparation method and application thereof |
-
2022
- 2022-01-18 CN CN202210056615.0A patent/CN114470235B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106540750A (en) * | 2016-10-21 | 2017-03-29 | 山东大学 | With visible light-responded small numerator modified catalysis material and preparation method |
| CN108619081A (en) * | 2018-05-22 | 2018-10-09 | 浙江理工大学 | A kind of photosensitive micropin and preparation method thereof, controlled release method |
| CN110787792A (en) * | 2019-11-19 | 2020-02-14 | 常州大学 | Bi with visible light response2Ti2O7-TiO2Preparation method of/RGO nano composite material |
Non-Patent Citations (1)
| Title |
|---|
| 宋建华 ; 钟翔 ; 邓钏 ; 杜亚洁 ; 潘蕾 ; 卫贤贤 ; .溴化氧铋制备及降解不同浓度罗丹明B研究.广州化工.(第07期), * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114470235A (en) | 2022-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lismont et al. | Metal‐organic framework nanoparticles in photodynamic therapy: current status and perspectives | |
| Wang et al. | Near-infrared light-induced dissociation of zeolitic imidazole framework-8 (ZIF-8) with encapsulated CuS nanoparticles and their application as a therapeutic nanoplatform | |
| Arruebo et al. | Development of magnetic nanostructured silica-based materials as potential vectors for drug-delivery applications | |
| CN104800846B (en) | A kind of core-shell gold rice material and its preparation method and application | |
| CN114470235B (en) | Application of bismuth-based metal organic framework material as light-operated drug carrier | |
| US20110196285A1 (en) | Hollow Mesoporous Silica Sphere Coated with Gold and Preparation Method Thereof and Use in Cancer Therapy | |
| Hua et al. | Composition‐Dependent enzyme mimicking activity and radiosensitizing effect of bimetallic clusters to modulate tumor hypoxia for enhanced cancer therapy | |
| CN102579318A (en) | Stable vitamin C sustained release preparation and preparation method thereof | |
| Chen et al. | Investigation of the mesoporous metal–organic framework as a new platform to study the transport phenomena of biomolecules | |
| CN110251477B (en) | Mecobalamin tablet and preparation method thereof | |
| WO2023087578A1 (en) | Urapidil hydrochloride injection and preparation method therefor | |
| Popova et al. | Experimental and theoretical study of quercetin complexes formed on pure silica and Zn-modified mesoporous MCM-41 and SBA-16 materials | |
| Bello et al. | Facile Synthesis and Size Control of 2D Cyclodextrin‐Based Metal–Organic Frameworks Nanosheet for Topical Drug Delivery | |
| Chang et al. | Precise Engineering of a Se/Te Nanochaperone for Reinvigorating Cancer Radio‐Immunotherapy | |
| JP7007300B2 (en) | New crystalline form of dapagliflozin and its manufacturing method and application | |
| Fu et al. | High-yield preparation of robust gold nanoshells on silica nanorattles with good biocompatiblity | |
| Tan et al. | Near-infrared-responsive nanoplatforms integrating dye-sensitized upconversion and heavy-atom effect for enhanced photodynamic therapy efficacy | |
| Patel et al. | A high yield, one-pot dialysis-based process for self-assembly of near infrared absorbing gold nanoparticles | |
| CN102276496B (en) | Aceglutamide compound and medicinal composition thereof | |
| CN113509559B (en) | CO and drug release synergistic therapeutic agent and preparation method and application thereof | |
| Biver et al. | Analysis of 4-dimethylaminopyridine (DMAP)-gold nanoparticles behaviour in solution and of their interaction with calf thymus DNA and living cells | |
| Tuninetti et al. | Shelter for biologically relevant molecules: Photoprotection and enhanced thermal stability of folic acid loaded in a ZIF-8 MOF porous host | |
| WO2023082219A1 (en) | Method for efficiently preparing nano-composite material in which metal-organic framework is loaded with selenium atoms and use thereof | |
| KR101583452B1 (en) | A pharmaceutical composition for treating gastrointestinal diseases | |
| Yang et al. | Light‐Triggered Hypoxia‐Responsive Nanoscale Metal‐Organic Frameworks for Highly Efficient Antitumor Treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |